A spate of regulatory warnings for India’s generic drug manufacturers will add a new emphasis on the quality of such medicines in an industry long dominated by the ability to deliver treatments as cheaply as possible, analysts say. In the short term, that is expected to benefit larger global competitors, such as Teva Pharmaceutical Industries […]Continue Reading